Filing Flows › Autolus Therapeutics (AUTL) › Q2 2025
Autolus Therapeutics (AUTL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Autolus Therapeutics (AUTL) reported revenue of $20.9M for the second quarter 2025 (Q2 2025) and +133% from the quarter before. Operating margin was -292.6%, net loss $47.9M (229.0% of revenue).
Autolus Therapeutics, Q2 2025: revenue $20.9M, operating margin -292.6%, net loss $47.9M, operating cash flow −$72.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.9M | +133% | — |
| Operating profit | −$61.2M | — | — |
| Net earnings | −$47.9M | — | — |
| Operating cash flow | −$72.8M | — | — |
What changed
Revenue was $20.9M in Q2 2025, up 133% from the previous quarter.
Operating costs exceeded revenue by $61.2M, an operating margin of -292.6%. The quarter ended with a net loss of $47.9M, narrower than the previous quarter's $70.2M loss. Non-operating items added $13.7M, -29% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$72.8M. Non-cash charges added back $2.1M of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items used $31.2M. Capital expenditures of $7.3M exceeded it, leaving free cash flow of −$80.1M.
Questions
What was Autolus Therapeutics' revenue in the second quarter 2025?
Autolus Therapeutics (AUTL) reported revenue of $20.9M for the second quarter 2025 (Q2 2025) and +133% from the quarter before.
Was Autolus Therapeutics profitable in the second quarter 2025?
Operating loss was $61.2M (-292.6% of revenue) and net loss $47.9M.